The key content of the policy proposal that representatives of multinational pharmaceutical companies with branches in Korea presented to the People Power Party’s election campaign committee was that the government should establish or improve the National Health Insurance and drug pricing system to encourage the use of highly effective but expensive innovative new drugs.

The policy proposal contained the request to pull forward the timing of insurance coverage for the companies' new drugs with measures such as preparing a separate source of finances other than the NHI finances by setting a new account for pharmaceutical expenses for severe diseases, introducing the ‘pre-(insurance) listing post-eval